Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review

Advancements in the understanding of tumor immunology in urothelial carcinoma (UC) have led to U.S Food and Drug Administration (FDA) approval of five novel anti-programmed cell death protein-1/ligand 1 (PD-1/L1) checkpoint inhibitors. In 2017, the anti-PD-L1 antibody atezolizumab and the anti-PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Jin, Cho, Kang Su, Koo, Kyo Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017288/
https://www.ncbi.nlm.nih.gov/pubmed/31940998
http://dx.doi.org/10.3390/cancers12010192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017288/
https://www.ncbi.nlm.nih.gov/pubmed/31940998
http://dx.doi.org/10.3390/cancers12010192

Ejemplares similares